Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$95.84 USD
+1.52 (1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $95.78 -0.06 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AXSM 95.84 +1.52(1.61%)
Will AXSM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXSM
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Other News for AXSM
Fairmount Funds Management LLC Expands Stake in Viridian Therapeutics Inc
TD Cowen Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Deep Track Capital, LP Increases Stake in Dynavax Technologies Corp
Strong Market Penetration and Commercial Success of Axsome’s Auvelity Justifies Buy Rating
Fairmount Funds Management LLC Acquires New Stake in ARCA biopharma Inc